Clinical Trial Update: A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II study comparing continuous versus syncopated dosing of CC-5013 (lenalidomide) for refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED